AA
ALNY icon

AlphaCentric Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

AlphaCentric Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Buy
1,390
+20
+1% +$6.03K 0.35% 100
2026
Q1 		$453K Buy
1,370
+75
+6% +$25.5K 0.45% 78
2025
Q4 		$515K Buy
+1,295
New +$573K 0.51% 60

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaCentric Advisors's ALNY Position: Q2 2026 in Review

AlphaCentric Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 1.5% in Q2 2026, buying an estimated $6.03K and bringing the position to 1,390 shares worth $418K. The position accounts for 0.35% of the portfolio, ranked #100.

AlphaCentric Advisors first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $515K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • AlphaCentric Advisors held 1,390 shares of Alnylam Pharmaceuticals worth $418K as of Q2 2026.
  • AlphaCentric Advisors bought 20 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.03K.
  • Alnylam Pharmaceuticals made up 0.35% of AlphaCentric Advisors's portfolio in Q2 2026, its #100 holding.
  • AlphaCentric Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • AlphaCentric Advisors's Alnylam Pharmaceuticals position peaked at $515K in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.